menu
    • menu
    [{"orgOrder":0,"company":"Trace Neuroscience","sponsor":"Unlearn","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"UNC13A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Trace Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trace Neuroscience \/ Unlearn","highestDevelopmentStatusID":"5","companyTruncated":"Trace Neuroscience \/ Unlearn"},{"orgOrder":0,"company":"Trace Neuroscience","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Trace Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trace Neuroscience \/ Third Rock Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Trace Neuroscience \/ Third Rock Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Trace Neuroscience

    Menu

    Trace Neuroscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trace Neuroscience

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Trace Neuroscience

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Unlearn

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Unlearn and Trace Neuroscience Partner to Optimize ALS Trials

                            Details : The partnership will support Trace Neuroscience as the company plans its upcoming Phase 1/2 in ALS, using Unlearn’s Digital Twin Generator for ALS.

                            Product Name : Undislcosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 01, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Unlearn

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trace Neuroscience

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Trace Neuroscience

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Third Rock Ventures

                            Deal Size : $101.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Trace Neuroscience Launches with $101M Series A for Genomic Medicine

                            Details : The financing will develop novel antisense oligonucleotides that restore UNC13A protein to re-establish healthy communication between nerves and muscle cells impacted by neurodegenerative disease.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Third Rock Ventures

                            Deal Size : $101.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth